{
    "clinical_study": {
        "@rank": "31592", 
        "acronym": "TOBA", 
        "arm_group": {
            "arm_group_label": "Treatment group", 
            "arm_group_type": "Experimental", 
            "description": "Treatment with Tack-IT Endovascular Staple"
        }, 
        "brief_summary": {
            "textblock": "A multi-center, post-CE Mark study designed to evaluate the performance of the Intact\n      Vascular Tack-IT Endovascular Stapler\u2122 in subjects with vascular flaps (e.g.;\n      post-angioplasty dissection) resulting from percutaneous transluminal balloon angioplasty\n      (PTA) of superficial femoral or popliteal artery(ies)."
        }, 
        "brief_title": "Tack Optimized Balloon Angioplasty (TOBA) Study", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Vascular Disease", 
        "condition_browse": {
            "mesh_term": [
                "Vascular Diseases", 
                "Peripheral Vascular Diseases", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Intact Vascular intends to conduct a prospective, single arm, multi-center, post-CE Mark\n      study designed to evaluate the performance of the Intact Vascular Tack-IT Endovascular\n      Stapler\u2122 in subjects with vascular flaps (e.g.; post-angioplasty dissection) resulting from\n      percutaneous transluminal balloon angioplasty (PTA) of superficial femoral or popliteal\n      artery(ies)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Rutherford clinical category 2, 3 or 4\n\n          -  ABI less than or equal to 0.90\n\n          -  Reference vessel diameter is between 2.5mm and 5.5mm\n\n          -  Target lesion has stenosis greater than or equal to 70% or is occluded\n\n          -  Target lesion is less than or equal to 10cm in length\n\n        Exclusion Criteria:\n\n          -  Previously implanted stent in the ipsilateral superficial femoral or popliteal artery\n\n          -  Target treatment area is severly calcified (e.g. circumferential calcification or\n             calcium plaque visible on plain fluoroscopy that extends far more than 5.0cm\n             continuously)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "138", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01663818", 
            "org_study_id": "TD 0009"
        }, 
        "intervention": {
            "arm_group_label": "Treatment group", 
            "intervention_name": "Tack-It Endovascular Stapler", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bonheiden", 
                    "country": "Belgium", 
                    "zip": "2820"
                }, 
                "name": "Patrick Peeters, MD"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Tack Optimized Balloon Angioplasty (TOBA) Study for Femoropopliteal Arteries Using the Tack-IT Endovascular Stapler", 
        "overall_official": [
            {
                "affiliation": "St. Blasius Hospital", 
                "last_name": "Marc Bosiers, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Park Hospital, Leipzig", 
                "last_name": "Dierk Scheinert, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite of new-onset major device-related adverse events.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01663818"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Intact Vascular", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Intact Vascular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}